Navigation Links
NutraCea Appoints New Chief Financial Officer
Date:11/6/2008

ysis, monthly forecasting, strategic/annual profit plans and Information Technology. She helped sell the Vehicle Switch Division to Delphi in late 2000 and restructured Automotive Controls for improved profitability.

Most recently, and prior to joining NutraCea, Hernandez-Longan was a Partner with Tatum LLC in their Financial Executive Practice. There she served as Interim Chief Financial Officer of companies such as Wells Dairy, makers of Blue Bunny Brand ice cream and Terlato Wine Group, a luxury wine producer and distributor where she had responsibility for all accounting, financial planning and M&A/joint venture activity.

Brad Edson, President and Chief Executive Officer of NutraCea commented, "We are extremely pleased to have Olga join our management team. Her expertise in financial reporting, international finance and M&A and joint ventures will serve NutraCea well as we continue to implement our strategic growth plan."

About NutraCea

NutraCea is a world leader in production and utilization of stabilized rice bran. They hold many patents for stabilized rice bran production technology and proprietary neutraceutical formulas ranging from arthritis, chronic bowel conditions, and effective diabetes control to cardiovascular disease treatment protocols. NutraCea's proprietary technology enables the creation of food and nutrition products to be unlocked from rice bran, normally a waste by-product of standard rice processing. Committed to helping the under fed, they're heavily involved in providing product and technology for developing countries through NutraCea's RiceAde feeding program. More information can be found in the Company's filings with the SEC and you can visit the NutraCea web site http://www.NutraCea.com.


'/>"/>
SOURCE NutraCea
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
2. Codexis Appoints Singapore Laboratories Managing Director
3. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
4. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
5. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
6. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
7. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
8. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
9. NeurogesX Appoints New Director to the Board
10. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
11. Premier Research Appoints Melissa Jones as Vice President, International Business Development

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...FirstCall/ -- Omeros Corporation (Nasdaq: OMER ) ...e third quarter ended September 30, 2009. For the ...rted a net loss of $3.9 million, or $1.34 per shar...2.54 per share, for the same period in 2008. For t...ny reported a net loss of $15.5 million, or $5.29 ...
(Date:11/19/2009)...-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS ), a...er to its shareholders, discussing the Company,s a...aceuticals Holdings, Inc. (CHBP), an integrated bi...ublic of China. The merger gives NeoStem a control.... Ltd., CHBP,s primary operating subsidiary and a ...
(Date:11/19/2009)...mber 19 MONITORING FORCE GmbH,anno...Flibanserin in the,indication treatment-relevant l...for orphan drug status designation with the Europe...nesia is a complication of the mainstay,treatment ...me of those,affected, since it may be disabling fo...
(Date:11/19/2009)...ne Synthesis Companies Form International Gene Syn...ces in Risk Reduction ,Five Member Companies Rep...city , (PRWEB) November 1...synthesis companies today announced agreement that...omote biosecurity in the gene synthesis industry. ...
Breaking Biology Technology:Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4
...eutics,Inc. (Nasdaq: FOLD ), a biopharmaceutical ...red pharmacological chaperones for the treatment o... results from its recently,completed Phase 2 clini...),for Fabry disease. As of November 2007, Amigal i...Genetic Therapies (HGT), a business unit of,Shire ...
...lved; Remaining Issues Pertain to cGMP Com...mpany Expects to Resolve cGMP Issues in the Next S...,Pharmaceuticals, Inc. (Nasdaq: IDEV ) today anno... from the U.S. Food and Drug Administration (FDA) ...uring and controls (CMC) NDA,supplement submitted ...
... Inc. enters into an exclusive, distribution agree...d New Zealand -, LA...Technologies &,Bioressources Inc. ("Neptune") (NAS...it has entered into an exclusive distribution agre...ional") for Australia and New,Zealand. AZPA Intern...
Other Biology Technology:Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease 2Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease 3Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease 4Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease 5Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease 6Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM) 2Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM) 3Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM) 4Nationwide product launch of NKO(R) planned for February 2008 in Australia and New Zealand 2Nationwide product launch of NKO(R) planned for February 2008 in Australia and New Zealand 3
(Date:11/23/2009)...of General Medical Sciences (NIGMS), part of the N...42.3 million for grants in scientific areas it ide...ed the GO grant program to stimulate biomedical re... American Recovery and Reinvestment Act (Recovery ...e to have a significant impact on a field of biome...
(Date:11/23/2009)...aled how environmental irritants such as air pollu... research published today in the American Journal...uthors of the study, from Imperial College London ...action inside the lungs that can trigger coughing ...n the air. They suggest that their findings may ul...
(Date:11/23/2009)...asty business, posing dangers to human health and ...s launching a new project with funding from the U....ets the fat and grease that contribute to millions...ners new tools to further reduce the risk of sewag...y" sewer systems, as opposed to "combined" systems...
Breaking Biology News(10 mins):NIGMS invests in scientific Grand Opportunities with Recovery Act funds 2NIGMS invests in scientific Grand Opportunities with Recovery Act funds 3Research reveals exactly how coughing is triggered by environmental irritants 2Lose the fat: Targeting grease to curtail sewer overflows 2Lilly Receives Fourth FDA Approval for ALIMTA 28R 29 28pemetrexed for injection 29 50746 1Lilly Receives Fourth FDA Approval for ALIMTA 28R 29 28pemetrexed for injection 29 50746 2Lilly Receives Fourth FDA Approval for ALIMTA 28R 29 28pemetrexed for injection 29 50746 3Lilly Receives Fourth FDA Approval for ALIMTA 28R 29 28pemetrexed for injection 29 50746 4Lilly Receives Fourth FDA Approval for ALIMTA 28R 29 28pemetrexed for injection 29 50746 5Lilly Receives Fourth FDA Approval for ALIMTA 28R 29 28pemetrexed for injection 29 50746 6Lilly Receives Fourth FDA Approval for ALIMTA 28R 29 28pemetrexed for injection 29 50746 7CSC to Kick Off National Blood Drive Campaign July 8 at Global Headquarters in Virginia 50743 1CSC to Kick Off National Blood Drive Campaign July 8 at Global Headquarters in Virginia 50743 2Smart for Life 28TM 29 Introduces HeroFiber 28TM 29 to Its Product Line 50740 1Smart for Life 28TM 29 Introduces HeroFiber 28TM 29 to Its Product Line 50740 2
...n human stem cell research, producing embryonic-li...ly speed up the development of treatments for life... The discovery made during a project undertaken wi...anch and the Synthecon Corporation in the United S...with an ethical and reliable source of human stem ...
...e US could soon be asked to approve a human trial ...brid of the HIV and Ebola viruses. Tests on monkey...s far more efficiently than any other method devel...iller viruses sounds horrifying, the risks should ...to develop an effective form of gene therapy to tr...
...sed on a recently published article in Environment...teria and a newly discovered group of marine worms...h uses sunken marine mammals as its sole source of...tal Microbiology, Dr Shana Goffredi and her collea...ia and the Osedax (bone-devouring) group of marine...
Other Biology News:Researchers propose measures to curb lion attacks in Tanzania 2Can two killers make a cure? 2
...loped the Easy-Titer Human IgM Assay Kit to addres...rform assay for Human IgM that eliminates the need...and-read assay that allows the accurate determinat...oximately 30 minutes. The Pierce Easy-Titer Human ...
...ilizer is an aqueous solution that contains a puri...g chemicals in a saline solution, pH 6.5 7.5, and...ne and 0.02% bromonitrodioxane as a preservative. ...bilizer for biologically active components in solu...
Cleanascite HC 16000 from Biotech Support Group
...e Stabilizer is a bovine protein-free alternative ...ueous solution that contains non-toxic chemicals i... - 7.2, and does not contain a preservative. This...other biomolecules that are absorbed or immobilize...
Biology Products: